Clinical Trial Expertise Key To Early-Stage Company Deals – Medtronic COO
This article was originally published in The Gray Sheet
Clinical data quality and integrity should be the main consideration for manufacturers evaluating a merger or alliance with an early-stage technology developer, according to Medtronic COO Bill Hawkins
You may also be interested in...
Mergers of drug discovery companies with device developers will remain rare, even as collaborations across the drug, device and biologics industries become more common, Medtronic COO Bill Hawkins maintains
Guidant says it will release a home-use version of its Latitude advanced patient management (APM) system upon gaining a CPT code to drive reimbursement
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.